5-aminovaleric acid has been researched along with Epilepsy, Temporal Lobe in 1 studies
5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd
5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.
Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because 5-aminovaleric acid (5-AV) has been implicated in modulation of the glutamine-glutamate-GABA metabolic pathway, we hypothesized that 5-AV would alter the expression of seizures in the MSO model of MTLE." | 7.80 | 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. ( Damisah, EC; Dhaher, R; Eid, T; Gruenbaum, BF; Gruenbaum, SE; Ong, C; Wang, H; Zaveri, HP, 2014) |
| "Both groups showed similar seizure frequency over days 3-21 (~1seizure/day)." | 5.40 | 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. ( Damisah, EC; Dhaher, R; Eid, T; Gruenbaum, BF; Gruenbaum, SE; Ong, C; Wang, H; Zaveri, HP, 2014) |
| " Because 5-aminovaleric acid (5-AV) has been implicated in modulation of the glutamine-glutamate-GABA metabolic pathway, we hypothesized that 5-AV would alter the expression of seizures in the MSO model of MTLE." | 3.80 | 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. ( Damisah, EC; Dhaher, R; Eid, T; Gruenbaum, BF; Gruenbaum, SE; Ong, C; Wang, H; Zaveri, HP, 2014) |
| "Both groups showed similar seizure frequency over days 3-21 (~1seizure/day)." | 1.40 | 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. ( Damisah, EC; Dhaher, R; Eid, T; Gruenbaum, BF; Gruenbaum, SE; Ong, C; Wang, H; Zaveri, HP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaher, R | 1 |
| Damisah, EC | 1 |
| Wang, H | 1 |
| Gruenbaum, SE | 1 |
| Ong, C | 1 |
| Zaveri, HP | 1 |
| Gruenbaum, BF | 1 |
| Eid, T | 1 |
1 other study available for 5-aminovaleric acid and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy.
Topics: Amino Acids, Neutral; Animals; Brain; Disease Models, Animal; Epilepsy, Temporal Lobe; Male; Methion | 2014 |